Role of syndecan-4 in breast cancer pathophysiology.
Humans
Female
Syndecan-4
/ genetics
Heparan Sulfate Proteoglycans
/ metabolism
Breast Neoplasms
/ pathology
Zoledronic Acid
Progesterone
Ligands
Receptors, Estrogen
Extracellular Matrix Proteins
MicroRNAs
Intercellular Signaling Peptides and Proteins
Trastuzumab
Integrins
Estrogens
Syndecan-1
Tumor Microenvironment
breast cancer
heparan sulfate proteoglycan
microRNA
syndecan-4
therapy
Journal
American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
13
9
2022
medline:
22
10
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Expression of the cell surface heparan sulfate proteoglycan syndecan-4 is dysregulated in breast cancer, the most frequent malignancy in women. High expression of syndecan-4 correlates with a worse survival in the subgroup of estrogen receptor negative and estrogen/progesterone-receptor negative patients. Aberrant expression of syndecan-4 in breast cancer involves both transcriptional and posttranscriptional mechanisms, including estrogen- and growth factor-dependent regulation, mutations in
Identifiants
pubmed: 36094435
doi: 10.1152/ajpcell.00152.2022
doi:
Substances chimiques
Syndecan-4
0
Heparan Sulfate Proteoglycans
0
Zoledronic Acid
6XC1PAD3KF
Progesterone
4G7DS2Q64Y
Ligands
0
Receptors, Estrogen
0
Extracellular Matrix Proteins
0
MicroRNAs
0
Intercellular Signaling Peptides and Proteins
0
Trastuzumab
P188ANX8CK
Integrins
0
Estrogens
0
Syndecan-1
0
NUP153 protein, human
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM